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Introduction
Attention-deficit hyperactivity disorder [ADHD] is a
pervasive childhood disorder. The most frequently
used treatments for ADHD are stimulant and psy-
chosocial treatments. Especially for psychosocial
treatments, however, studies on prediction and
moderation of treatment-response are virtually non-
existent [25]. In contrast, in other childhood psy-
chopathological conditions, such as Oppositional
Defiant Disorder (ODD) or Conduct Disorder (CD),
several studies have been conducted on outcome
prediction of psychosocial treatments [8].
The few outcome prediction studies on psychoso-
cial treatments of ADHD available use data from the
MTA study [22]. The MTA study is the largest treat-
ment study to date, which compared the outcome of 4
treatment conditions: (1) medication, (2) intense
behavior therapy, (3) combined treatment, consisting
of medication and intense behavioral therapy treat-
ment, and (4) community care. Results indicated that
all 4 conditions showed significant reduction in
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j Abstract Objective: The present
study investigated the predictive
power of anxiety, IQ, severity of
ADHD and parental depression on
the outcome of treatment in chil-
dren with ADHD. Method: Fifty
children with ADHD (ages 8–12)
were randomized to a 10-week
treatment of methylphenidate or
to a treatment of methylphenidate
combined with multimodal
behavior therapy. Prior to treat-
ment predictors were assessed.
Outcome was assessed separately
for parents and teachers on a
composite measure of inattentive,
hyperactive, oppositional- and
conduct disorder symptoms. Re-
sults: There was neither a signifi-
cant difference between the two
treatments at baseline nor did
treatment condition predict out-
come. Therefore the data were
collapsed across the two treat-
ments. A combination of anxiety
and IQ predicted teacher-rated
outcome, explaining 18% of the
variance. Higher anxiety and
higher IQ’s indicated better treat-
ment outcome. There were no
significant predictors of the par-
ent-rated outcome. Conclusions:
This study showed a small but
significant predictive effect of IQ
and anxiety on treatment outcome
in children with ADHD. Clinical
implications: This study supports
the idea that for the treatment of
ADHD children with comorbid
anxiety and higher IQ respond
better to the two most used treat-
ments for ADHD.
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ADHD and related symptoms. However, the medica-
tion and the combined treatment showed greater
improvements in ADHD and related symptoms
compared to the community care and intense
behavior therapy alone. Surprisingly, the medication
and the combined treatment did not differ signifi-
cantly on any comparison.
In this study, four predictors for psychosocial
treatment outcome are examined: anxiety, intelli-
gence, severity of ADHD and parental depression.
Most research to date has been aimed at the predictive
value of the child’s anxiety for psychosocial treatment
outcome in the MTA study [16, 21, 23]. Also, one
study examined the predictive value of intelligence,
severity of ADHD and parental depression on psy-
chosocial treatment outcome in the MTA study [25].
For all four predictors, anxiety, IQ, parental
depression and severity of ADHD, psychosocial and
methylphenidate studies are reviewed.
j Anxiety
It has been speculated that comorbid anxiety may
influence the outcome of treatment for ADHD [16,
23, see for review 12]. Data of the MTA study have
shown that comorbid anxiety improved intense
behavior therapy outcome [16, 21, 23], meaning that
higher anxiety predicted a more positive treatment
outcome.
In contrast, however, several methylphenidate
studies have shown that comorbid anxiety (i.e. higher
anxiety) worsens treatment outcome (e.g., [7, 12, 29,
36]). In the MTA study, however, the presence of
anxiety disorders did not predict worse response to
methylphenidate [21]. Owens et al. [25] further
examined predictors of treatment response in the
MTA study, using a categorical measure of ‘‘excellent
response’’, rather than a continuous outcome mea-
sure, as used in earlier analyses of the MTA data [16,
21]. In that study, anxiety of the child neither pre-
dicted response to behavioral treatment nor to
methylphenidate treatment. In sum, comorbid anxiety
of the child improves behavior therapy outcome (e.g.
[16, 21, 23]), but worsens outcome for methylpheni-
date treatment [7, 12, 29, 36].
j IQ
Lower IQ has been suggested to predict worse treat-
ment response to behavioral treatments, because
children with lower IQ would be less able to learn new
skills and therefore would benefit less from behavioral
treatments [17]. To date, only one study has examined
the predictive value of childhood intelligence on
psychosocial treatment response in ADHD children
[25]. Using data of the MTA study, it was shown that
IQ in the presence of parental depressive symptoms
and severity of childhood ADHD, was a predictor of
response in the methylphenidate and combined
treatment conditions; a lower IQ predicted worse
treatment response. Secondary analyses showed that
lower IQ-levels were more strongly related to a worse
treatment response in the medication condition than
in the conditions including psychosocial treatments.
The effects of IQ in methylphenidate studies have
been mixed [7, 12, 36]. Buitelaar et al. [7], for exam-
ple, found in children with strong methylphenidate
response that lower IQ predicted worse response to
medication treatment. In children with weaker
methylphenidate response, however, IQ was no longer
a significant predictor. In an extensive review of
methylphenidate prediction studies, Gray and Kagan
[12] concluded that intelligence bears little or no
relation to methylphenidate responder status.
j Severity of ADHD
Regarding psychosocial studies, only one study using
MTA data is available on the predictive power of
severity of ADHD [25]. In the combined condition of
the MTA study, worse outcome has been reported for
children displaying high levels of ADHD symptoms at
baseline [25]. Studies on methylphenidate treatment
have reported severity of the ADHD as predictor of
treatment response, with higher levels of baseline
ADHD predicting poorer outcome [12, 36].
j Parental psychopathology
The influence of parental psychopathology on the
outcome of treatment in ADHD has not received
much research attention, although parental psycho-
pathology may impact parents’ ability to effectively
implement behavior management techniques [8].
Owens et al. [25], using the MTA study data, found
parental depression to be predictive of worse treat-
ment outcome in the medication condition, but not in
the psychosocial condition. Hoza et al. [15], using
data of the MTA study, found a relation between
maternal self-esteem and treatment outcome in all
four MTA treatment conditions. Mothers with higher
self-esteem showed better treatment outcome, which
supports the idea that parental psychopathology is
related to treatment outcome.
The present study examined the predictive power
of parental depression, severity of ADHD, IQ and
anxiety of the child for treatment outcome in medi-
cation naı¨ve children aged 8–12 years old, in two
treatments conditions: (1) methylphenidate treatment
and (2) combined multimodal behavior therapy and
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methylphenidate treatment. For both the methylphe-
nidate and combined treatment, higher severity of
ADHD, lower IQ and higher parental depressed mood
were expected to worsen treatment outcome. Higher
anxiety, however, was expected to worsen treatment
outcome with methylphenidate treatment and im-
prove outcome with combined treatment. Since
informant agreement in the rating of ADHD has been
low (e.g., [1, 33, 39]), parent and teacher ratings were
analyzed separately.
Method
j Participants
Participants were 50 children between the age of 8 and
12 years (M = 9.9, SD = 1.2). These children also par-
ticipated in the treatment-outcome study of Van der
Oord, Prins, Oosterlaan and Emmelkamp [38]. Chil-
dren were referred for diagnosis and treatment of
ADHD by school psychologists, paediatricians or gen-
eral practitioners to five different child psychiatric
outpatient clinics in the Netherlands. Inclusion criteria
for participating in this study were: (1) a DSM-IV
diagnosis of ADHD as established with the parent
version of the Diagnostic Interview Schedule for Chil-
dren (DISC-IV) [33] and (2) an estimated full scale IQ of
75 or above, based on a short version of the Wechsler
Intelligence Scale for Children-Revised (WISC-R) [40].
In this study, using the short version of the WISC-R,
96% of the children had an IQ of 80 or higher. Exclusion
criteria for this study were inadequate mastering of the
Dutch language by the child or by both parents, and a
history of methylphenidate use.
The ADHD, ODD and CD sections of the DISC-IV
parent version [11, 33] were administered by a trained
clinical child psychologist. The DISC-IV is a struc-
tured diagnostic interview that generates DSM-IV
diagnoses. Adequate reliability and validity have been
reported for precursors of the DISC-IV [11, 32]. Using
the DISC-IV, 31 children met DSM-IV criteria for
ADHD combined type, 16 met criteria for ADHD
inattentive type and 3 children met criteria for the
hyperactive/impulsive type. Twenty-three of these
ADHD children showed comorbidity with ODD, and
two of these children met criteria for an additional
DSM-IV diagnosis of CD.
j Procedure
Before inclusion in the study, parents gave written
informed consent and children gave their verbal
consent. A local medical ethics committee approved
the study. Participants were randomly assigned to
treatment with methylphenidate or combined treat-
ment of methylphenidate and multimodal behavior
therapy. The week before the beginning of the treat-
ment, the pre-test was conducted: parents and
teachers completed questionnaires and children were
assessed at the outpatient clinic. Within a week fol-
lowing the last session of the multimodal behavioral
treatment, approximately 11 weeks after the pre-test,
participants in both treatment arms received the post-
test.
j Treatment
Methylphenidate treatment
A four-week, pseudo randomized multiple blind pla-
cebo controlled crossover medication design, as de-
scribed by the MTA [13], was used for individual
methylphenidate dose titration. The best dose was
evaluated for 5 weeks (4 week titration, 1 week eval-
uation period), and then the optimal dose was sub-
scribed for 5 weeks. In the titration trial 5, 10 and
20 mg of methylphenidate and placebo were admin-
istered in a pseudo random order twice daily at
breakfast and at lunch. The highest dose never ex-
ceeded 0.9 mg per kg of the body weight. During
these four weeks, the effects of methylphenidate and
side-effects were monitored daily at school and at
home by teachers and parents, respectively, using
rating scales, measuring symptoms of ADHD, ODD,
impairment and side-effects (see [13]). After these
four weeks, five independent clinical raters, using a
standardized manual (as described in [31]), blindly
reviewed mean dose-response graphs, following
which the child was classified as responder, placebo-
responder or non-responder to methylphenidate.
During this evaluation period of 1 week, children
were medication free. By consensus each child’s best
dose was selected. Following the consensus proce-
dure, a child psychiatrist prescribed the selected best
dose (if not placebo) for the child for the remaining
five weeks of the study.
Of the 45 titrated children (see Results section for
drop-out rates), one child did not complete titration
due to side effects, however, post-test scores of this
participant were collected. Of the remaining 44 chil-
dren, 25 (59%) were assigned to an individually,
optimally titrated dose of methylphenidate, with an
average individual dose of 20.8 mg/day (SD = 10.18).
The remaining 19 children were classified as placebo
responders. Placebo response may reflect a com-
pression of ratings that is an artefact of rating
methodology. Without objective measures, real pla-
cebo-responses and rating artefacts are difficult to
differentiate (Pelham in [13]). Therefore, manualized
instructions for psychiatrists included the option of
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prescribing 5 mg twice daily for placebo-responders,
in case of recurring ADHD symptoms during the
medication-free week. Using this procedure, 8 chil-
dren were prescribed 5 mg twice a day. During the
remaining 5 weeks of methylphenidate treatment
subjects were specifically instructed to remain on the
assigned dose. However, in case severe symptoms or
side effects emerged, the child psychiatrist was con-
sulted and dose adjustments could be made. In 7 of
the 44 titrated children (15%) the dose was changed
from titration to post-test. In three children the dose
was lowered, due to emerging side effects. In four
children the dose was raised, because of re-emerging
ADHD symptoms.
Combined multimodal behavior therapy and
methylphenidate treatment
In addition to the methylphenidate treatment de-
scribed above, children in the combined treatment
condition received a manualized multimodal behavior
therapy, which integrated family-based and school-
based interventions with cognitive behavior therapy
of the child. The multimodal behavior therapy started
simultaneously with the methylphenidate treatment.
The parental behavioral therapy module consisted
of 10 weekly sessions of 90 min group therapy for 4
or 5 parent couples. This parent training was based on
the training developed by Barkley [3]: ‘‘Defiant chil-
dren: a clinicians manual for parent training’’. The
teacher-training module was based on the manual
developed by Pelham [27]: ‘‘Attention deficit hyper-
activity disorder, diagnosis, nature, etiology and
treatment’’ and consisted of a brief two-hour work-
shop for the teacher of the participating child, in
which other teacher-colleagues could participate. Fi-
nally, the child cognitive-behavior therapy module
consisted of 10 weekly 75 min group sessions in
which 4 or 5 children participated. Cognitive-behav-
ioral techniques consisted of the children acquiring
problem-solving techniques; the program used was
adapted from Kendall and Braswell [18]. More de-
tailed information on these treatment modules has
been described in Van der Oord et al. [38].
j Predictors
IQ: Revised Wechsler Intelligence Scale for Children
(WISC-R)
Four subtests of the WISC-R were administered to
assess intelligence. Subtests of this short version were:
Vocabulary, Arithmetic, Block Design, and Picture
Arrangement. The estimation of the IQ as obtained by
these four subtests correlates between r = .93 and
r = .95 with Full Scale IQ [14].
ADHD symptom severity: Disruptive Behavior Disorder
Rating Scale (DBDRS)
The DBDRS [24, 26] was developed to obtain parent
and teacher ratings of disruptive behavior disorder
symptoms, based on the DSM-IV criteria. The DBDRS
consists of 42 items and contains four subscales:
Inattention, Hyperactivity/Impulsivity, ODD and CD.
Parents and teachers rate the behavior of the child on
a 4-point Likert scale ranging from 0 (not at all) to 3
(very much). The Dutch translation of the DBDRS has
adequate reliability (Cronbach’s alpha range = .88–
.94) [24]. Two subscales were used for assessment of
ADHD symptoms severity: Inattention (9 items) and
Hyperactivity/Impulsivity (9 items). The Inattention
and Hyperactivity/Impulsivity pre-test subscale
scores were summed into one ADHD score. Higher
scores on the DBDRS indicate more severe symptoms.
Trait anxiety: State Trait Anxiety Inventory for
Children (STAIC)
For assessment of anxiety, the trait anxiety scale of the
Dutch version of the State- Trait Anxiety Inventory
for Children (STAIC) [2, 35] was used. This trait
anxiety scale consists of 20 items. Items of the STAIC
are rated by the child on a 3-point Likert scale ranging
from 1 (almost never) to 2 (often). Reliability of this
scale is high in a Dutch sample (Cronbach’s alpha =
.80) [2]. Higher scores indicate more severe anxiety
symptoms.
Parental depression: Center for Epidemiologic Studies
Depression Rating Scale (CES-D)
The CES-D was developed to assess depressive
symptoms in the past week. The primary care-taker of
the child rated their depressive symptoms on the CES-
D. The CES-D consists of 20 items rated on a 4-point
Likert scale ranging from 0 (almost never) to 3 (most
of the time or always). Internal consistency (Cron-
bach’s alpha .92) of the Dutch version of the CES-D is
high [6]. Higher scores indicate more depressive
symptoms.
Criterion
Following Sonuga-barke, Daley and Thompson [34],
treatment outcome was measured using a composite
score of disruptive symptoms. All four post-test
subscale (Inattention, Hyperactivity/Impulsivity,
ODD and CD) scores of the DBDRS (described above)
were used for computation of this composite score.
First, the four scale scores were z-transformed (based
on data from the present sample) and then scores
were averaged for parents and teachers separately.
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This composite reduces multiple testing and increases
the reliability of the outcome estimate. Cronbach’s
alpha for this composite score was high for both
teacher (.83) and parent ratings (.80).
Statistical analyses
First, we tested the effectiveness of the two treatments
with repeated measures ANOVAs. In these repeated
measures ANOVAs the treatment outcome was the
dependent variable, and the treatment condition
(methylphenidate or combined treatment) was the
between treatment variable (see also Van der Oord,
Prins, Oosterlaan and Emmelkamp [38]). Further, to
assess potential differential treatment response, on
our newly constructed parent and teacher composite
scores (the criterion), two separate linear regression
analyses were conducted with the treatment condition
as predictor and the composite score as the criterion.
To assess associations between predictors and com-
posite scores, Pearson correlations were computed.
To assess the predictive effect of anxiety, IQ,
severity of ADHD, and parental depression on treat-
ment outcome, two separate stepwise multiple linear
regression analyses were performed. The first had the
parental composite score as criterion and the second
regression analyses had the teacher composite score
as criterion. In both analyses, baseline trait anxiety,
IQ, parent-or teacher rated ADHD symptom severity
and parental depressed mood were entered as pre-
dictors. Since previous research is scarce and no
specific predictions could be made about order of
entry of the predictors, predictors were entered
simultaneously in the regression model.
Results
Of the 50 children included in the study, 23 children
were randomized to the methylphenidate treatment
and 27 to the combined treatment condition. Five
children dropped out, due to various reasons. One
child refused to participate after randomization to the
methylphenidate treatment condition. Further, one
child did not show up at post-test and two parent
couples dropped out, because of marital problems
and inconvenient time of treatment, respectively.
Criterion for treatment attendance in the combined
treatment condition was attending at least 75% of all
treatment sessions. One child was omitted from the
analyses because this criterion was not met.
j Differences between treatments
The repeated measure ANOVAs for treatment out-
come differences showed a consistent pattern. On all
measures significant improvements were found from
pre-to post-test. Further, there were no significant
time by treatment condition interactions. These
analyses showed that both treatment conditions did
not differ in their improvement from pre-to post-test.
Also, all time by treatment condition effect sizes were
small and there were no treatment differences in post-
test doses of methylphenidate (see [38]).
Descriptives of the two composite scores and the
four predictors are shown in Table 1. Univariate
ANOVAs showed no significant differences between
the two treatment conditions on any of the predictors
or criterion variables (Table 1). Additionally, two
linear regression analyses were conducted with
treatment condition as predictor and the parent- and
teacher composite scores, respectively, as criterion
variables. In both analyses, treatment condition was
no significant predictor of outcome. Since there were
no treatment differences on any of the analyses, data
were collapsed across the two treatments. Pearson
correlations between baseline and dependent vari-
ables are displayed in Table 2.
The stepwise multiple regression analysis of the
parent rated composite score revealed no significant
Table 1 Means (M), Standard Deviations (SD), and F statistics (F) for predictor and criterion variables
Methylphenidate
treatment (n = 21)
Methylphenidate + Multimodal
behavioral treatment (n = 24)
M SD M SD F
IQ (WISC-R) 96.81 12.10 100.04 17.26 .51
Anxiety (STAIC) 33.19 5.70 32.87 6.77 .03
ADHD parent (DBDRS) 30.50 9.50 27.91 8.51 .91
ADHD teacher (DBDRS) 27.43 11.62 26.52 7.93 .09
Depressed mood (CES-D) 6.81 4.57 6.94 8.14 .00
Parent: disruptive symptoms composite ).06 .83 ).03 .72 2.32
Teacher: disruptive symptoms composite .19 .92 ).17 .63 .02
Note: WISC-R = Wechsler Intelligence scale for Children-Revised, STAIC = State Trait Anxiety Inventory for Children, DBDRS = Disruptive Behavior Disorder Rating
Scale, CES-D = Center for Epidemiologic Studies-Depression
*P £ .05, **P £ .01
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predictors. Both anxiety and IQ significantly pre-
dicted the teacher rated composite score and ex-
plained 18% of the variance (R2 = .18, adjusted
R2 = .14, F (2, 39) = 4.22, P = .02). Anxiety alone
accounted for 9.4% of the variance (R2 = .09, adjusted
R2 = .07, F (1, 40) = 4.19, P = .05) and IQ for an
additional 8.4% of the variance (DR2 = .08, F (1,
39) = 3.97, P = .05).
Inspection of Pearson correlation coefficients
showed a negative association between anxiety and
the teacher rated composite score, indicating that
high anxiety was associated with low teacher com-
posite scores, that is a better treatment outcome.
Moreover, IQ showed a negative association, with
high IQ being related to low teacher composite scores
(i.e., better treatment outcome).
Additionally, it was examined whether the signifi-
cant predictors interacted with treatment condition.
None of the significant predictors showed a signifi-
cant interaction with treatment condition. This sup-
ports the idea that predictors are identical for both
treatments. Finally, it was examined whether the sig-
nificant predictors interacted with baseline levels of
ADHD symptoms. Both IQ and anxiety showed no
significant interaction with baseline levels of ADHD
symptoms. This supports the idea that both IQ and
anxiety are associated with treatment outcome,
regardless of baseline levels of ADHD.
Discussion
Especially for psychosocial treatment in children with
ADHD, studies on the prediction of treatment out-
come are virtually non-existent [25]. However, re-
analyses of the MTA-study results have assessed
predictors of psychosocial treatment outcome [16, 21,
23, 25]. The present study examined the predictive
power of anxiety, IQ, severity of ADHD and parental
depression for the outcome in children with ADHD of
the two most widely used treatments for childhood
ADHD: methylphenidate and a combination of
methylphenidate and multimodal behavioral treat-
ment. This study showed a small, but significant
predictive effect of IQ and anxiety on treatment out-
come in childhood ADHD. For both the methylphe-
nidate and combined treatment predictors were
identical. Baseline ADHD symptoms could not ac-
count for the predictive effect of IQ and anxiety for
outcome. IQ and anxiety were unrelated, which
underlines that both had a unique influence. Children
with higher anxiety had a better treatment outcome,
as was the case for children with higher IQ scores.
Severity of the baseline ADHD symptoms and
parental depressed mood were of no influence on
treatment outcome.
Contrary to most methylphenidate studies, no ad-
verse effect was found for comorbid anxiety on out-
come as measured both in methylphenidate and
combined treatment [12]. In contrast, the present
study showed higher levels of IQ to be predictive of
better treatment outcome. Most methylphenidate
studies reporting the effects of anxiety, have used
short term, fixed dosing procedures (e.g. [10, 29]),
often using prediction models in which ‘‘change
models’’ are used: the differential predictive effect of
methylphenidate versus placebo. Our study, however,
focused on the predictions of response to long-term
optimally dosed methylphenidate treatment and did
not employ a change models approach (e.g. [9, 36]).
Similarly, in the MTA study, also long-term optimally
dosed methylphenidate treatment was used, and no
predictive effect of anxiety was reported for the
medication only condition [16, 21]. However, in the
MTA study, children with a comorbid diagnosis of
anxiety responded better to the combined treatment
of medication and behavior therapy [21, 23], and to
behavior therapy alone.
In line with the MTA study, we found comorbid
anxiety to improve treatment outcome, however, this
improvement was found for both the methylphenidate
and the combined treatment conditions. Differences
between parents of anxious children with ADHD and
parents of non-anxious children with ADHD may
Table 2 Pearson correlations between predictor and criterion variables
2.
Anxiety
3. ADHD-
Parent
4. ADHD-
Teacher
5. Depressed
mood
6. Parent: disruptive
symptoms composite
7. Teacher: disruptive
symptoms composite
1. IQ (WISC-R) .02 ).19 ).09 .05 .01 ).30*
2. Anxiety (STAIC) 37* ).34* .14 .13 ).31*
3. ADHD-parent (DBDRS) ).28 .33* .18 ).16
4. ADHD-Teacher (DBDRS) ).13 ).36* .23
5. Depressed mood (CES-D) .20 ).10
6. Parent: disruptive symptoms composite ).19
7. Teacher: disruptive symptoms composite
Note: WISC-R = Wechsler Intelligence scale for Children-Revised, STAIC = State Trait Anxiety Inventory for Children, DBDRS = Disruptive Behavior Disorder Rating
Scale, CES-D = Center for Epidemiologic Studies-Depression
*P £ .05, **P £ .01
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have mediated or moderated treatment outcome. For
example, several studies have shown more anxiety
symptoms in the mothers of children with ADHD and
comorbid anxiety compared to mothers of children
with ADHD without comorbid anxiety [5, 28]. Also,
parental over protectiveness was found to be related
to comorbid child anxiety in children with ADHD
[28]. It may be speculated that these anxious, over-
protective parents of anxious children with ADHD
were more inclined to comply to treatments and may
have been better able to follow the treatment regimen
than the parents of the non-anxious children with
ADHD, resulting in better treatment outcome for the
anxious children with ADHD for both the methyl-
phenidate and combined treatment. As we, in our
study, have not assessed parental anxiety symptoms
and over protectiveness, this needs to be tested in
future research.
Previous research has found anxiety to be a pre-
dictor of parent-rated treatment outcomes [21, 23],
while other researchers [25] have reported no pre-
dictive effect of anxiety on parent- and teacher rated
ADHD and ODD outcomes. In the present study,
significant predictors were found for teachers’ but not
for parent rated outcome. Some suggest teacher’s
ratings to be the most accurate, but research is
inconclusive [4, 20, 30].
In the present study, higher IQ-levels were a sig-
nificant predictor of better treatment response. Other
researchers have reported higher IQ-levels to be
associated with better methylphenidate response (e.g.,
7]), but only in strong methylphenidate responders.
Owens et al. [25] also reported IQ to be a predictor of
treatment response in both the methylphenidate as
well as the methylphenidate and behavioral treatment
conditions, but only in the presence of high baseline
ADHD and parental depressive symptoms. In samples
of antisocial children, low IQ has been suggested to
worsen psychosocial treatment response, because
children with lower IQs would be less able to learn
new skills and therefore would benefit less from
behavioral treatment [17]. Our supplementary analy-
ses did not support the idea that the effect of IQ was
related to the ability to learn new skills, as in both the
methylphenidate and combined condition IQ was a
significant predictor, and no significant interaction
was found between treatment outcome and IQ. Due to
our small sample size, possibly we were not able to
detect differences. Alternatively, a third not measured
variable related to IQ, for example compliance or
social economical status, was related to the predictive
effect of IQ.
Contrary to Owens et al. [25], we did not find
parental depression and severity of ADHD symptoms
to be predictive of treatment outcome. Possibly this
was caused by the higher rate of parents with de-
pressed mood in the sample studied by Owens et al.
[25]. Inspection of the sample’s mean depression
score, however, shows that similar to our study,
mothers of children in the Owens et al. study were not
severely depressed. Similarly, with regard to severity
of the disorder, children in our sample may have
displayed less severe levels of ADHD than the children
participating in the MTA study. However, the children
participating in this study displayed severe baseline
levels of ADHD symptoms (see [38]) and all children
fulfilled DSM-IV criteria for ADHD. Further, the MTA
study included the combined subtype of ADHD only,
while our study also included children of the ADHD-
inattentive subtype. Buitelaar et al. [7], however,
consistent with our study, also did not find severity of
the disorder, as rated by parents and teachers, to be
predictive of methylphenidate treatment outcome. In
that study, severity of the disorder was only found to
be predictive of treatment outcome as measured by an
independent observer’s rating during a lab test.
Limitations
We acknowledge that our study incorporated a lim-
ited set of predictors. Examination of other predic-
tors, such as parenting style, comorbid ODD/CD,
compliance and receiving public assistance, would
also be important. Others have found high levels of
maternal ADHD to be a predictor of worse response
to psychosocial treatment in preschoolers with ADHD
[34]. It is suggested that parental ADHD interferes
with the treatment of the child’s ADHD, as parents
may have difficulty adhering to a treatment plan [41],
which may apply to both psychosocial and methyl-
phenidate treatment. Due to power limitations, how-
ever, we limited our analyses to a selection of the most
important and empirically based predictors. Further,
the amount of variance accounted for by IQ and
anxiety was small, never exceeding 10%. It is therefore
unlikely that any single variable will be an effective
predictor of a child’s individual treatment outcome
[12]. A further limitation of the present study is the
small sample size. Due to the small sample size, we
possibly did not find a treatment condition effect for
the predictors, as for the inclusion of an interaction
term in a regression analyses often a larger sample is
needed. Another limitation of our study is the open
label nature of the study. Participants and researchers
were not blind to the treatment condition the child
was given, possibly influencing post-test outcome
scores. However, regardless of the open-label nature
of the study no treatment differences were found. Our
study focused on predictors for treatment outcome,
regardless of how they might have been related to
outcome. Future research should explore mechanisms
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by which predictors exert their influence on treatment
outcome [19].
Finally, a non-measured variable may be related to
both anxiety and intelligence. For example, comorbid
ODD/CD may be related to both anxiety and intelli-
gence. Jensen et al. [16], however, found anxiety to
improve treatment outcome of behavioral treatments
regardless of the presence of ODD/CD. Also, compli-
ance to treatment may be an underlying variable
causing both children with higher intelligence and
higher levels of anxiety to respond better to treatment.
Children with higher intelligence more easily may
understand the necessity to comply with the medi-
cation and behavioral treatment. Moreover, due to
their anxious symptoms, children with higher levels
of anxiety may be more inclined to comply with
treatment. Thiruchelvam, Charach and Schachar [37],
however, did not find an association between IQ,
anxiety and long-term compliance to stimulant med-
ication. Clearly, more research on the interrelations of
these variables is warranted.
All in all, this study shows that children with higher
IQ and higher levels of anxiety are more likely to re-
spond better to methylphenidate and to multimodal
behavioral treatment combined with methylphenidate
treatment as rated by teachers, but not by parents.
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